Key result
This letter questions whether the bolus dose of intracoronary Premarin used in a prior study produced pharmacological rather than physiological estrogen levels.
Why the study?
Does intracoronary conjugated estrogen affect coronary vasomotion and myocardial ischemia in patients undergoing percutaneous coronary angioplasty?
Does intracoronary conjugated estrogen affect coronary vasomotion and myocardial ischemia in patients undergoing percutaneous coronary angioplasty?
Answers are grounded in this paper and cite their sources.
This letter highlights the importance of distinguishing between acute pharmacological effects and long-term physiological replacement effects when studying intracoronary estrogen administration.
We read with interest the publication by Lee et al 1 describing the potential mechanisms and effects of intracoronary conjugated estrogens on coronary vasomotion and myocardial ischemia in patients undergoing percutaneous coronary angioplasty. We were surprised at the very high bolus dose of intracoronary Premarin (Wyeth-Ayerst) given-5 mg into the left coronary system (postmenopausal replacement doses, given orally, range from 0.625 to 1.25 mg daily). The initial exposure dose to the coronary circulation would have been enormous; however, the local concentrations of estrogens are not discussed. It is important and relevant to the interpretation of this study to distinguish between acute, pharmacological effects and long-term replacement effects. How can the authors state that physiological levels of estrogen were achieved? They report that "end-study" coronary sinus 17-estradiol levels were raised in their subjects (mostly male) receiving Premarin, but the levels exceed that reported in women taking oral replacement. The authors state that the levels achieved were similar to those of premenopausal women and were, therefore, physiological.
No takes yet. Share an insight, caveat, or question.
Webb et al. (2003) conducted a letter in percutaneous coronary angioplasty. Intracoronary conjugated estrogens (Premarin) was evaluated. This letter questions whether the bolus dose of intracoronary Premarin used in a prior study produced pharmacological rather than physiological estrogen levels.
Synapse has enriched 10 related papers. Consider them for comparative context: